Home > Oncology > ASCO 2024 > Osimertinib significantly improves progression-free survival for patients with unresectable stage III, EGFR-mutated NSCLC

Osimertinib significantly improves progression-free survival for patients with unresectable stage III, EGFR-mutated NSCLC

Presented by
Prof. Suresh Ramalingam, Emory University, GA, USA
Conference
ASCO 2024
Trial
Phase 3, LAURA
Treatment with osimertinib in patients with unresectable stage III, EGFR-mutated non-small cell lung cancer (NSCLC) after definitive chemoradiotherapy does strongly improve progression-free survival (PFS), as shown in phase 3 LAURA trial.

In unresectable stage III NSCLC following chemoradiotherapy without progression, consolidation therapy with durvalumab is standard of care [1]. However, benefit of consolidation with durvalumab is uncertain in patients with EGRF-mutated NSCLC [2].

Based on real world-data and a result from a phase 2 study, phase 3 LAURA trial (NCT03521154) evaluated the efficacy and safety of EGFR-tyrosine kinase inhibitor osimertinib in patients with unresectable, stage III, EGFR-mutated NSCLC with no progression during or following definitive chemoradiotherapy.

A total of 216 patients were 2:1 randomised to receive osimertinib (80 mg daily) until disease progression or toxicity or placebo. Participants receiving placebo were allowed to cross-over to osimertinib after progression. The primary outcome measurement was PFS. Prof. Suresh Ramalingam (Emory University, GA, USA) presented the primary results [3].

Osimertinib demonstrated a statistically significant and clinically meaningful improvement in PFS. Median PFS in participants treated with osimertinib was 39.1 months (95% CI 31.5-NA) versus 5.6 months (95% CI 3.7-7.4) in participants treated with placebo (HR 0.16; 95% CI 0.10 ‚Äď0.24; P<0.001). At 24 months, PFS rate in both arms was 65% and 13%, respectively. PFS benefit with osimertinib was observed in all key subgroups (sex, age, stage, EGFR mutation, response to prior chemoradiotherapy).

In addition, the objective response rate was improved by osimertinib (57% vs 33%) as was the median duration of response (36.9 vs 6.5 months). Participants treated with osimertinib were less likely to develop new lesions (22% vs 68%), particularly in the brain (8% vs 29%). Overall survival data are not yet mature. In the placebo arm, 81% of patients did cross over to osimertinib after confirmed progression.

Based on these primary results, Prof. Ramalingam expected ‚Äúosimertinib to become the new standard of care for patients with unresectable stage III, EGFR-mutated NSCLC who have not progressed after definitive chemoradiotherapy.‚ÄĚ

  1. Spigel DR, et al. J Clin Oncol. 2022; 40: 1301-1311.
  2. Naidoo J, et al. J Thorac Oncol. 2023; 18: 657-663.
  3. Ramalingam SS, et al. Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) NSCLC: primary results of the phase 3 LAURA study. Abstract LBA4. ASCO Annual Meeting 2024, May 31-June 4, Chicago, IL, USA.

Medical writing support was provided by Marten Dooper, PhD.

Copyright ©2024 Medicom Medical Publishers



Posted on